2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis*

Clinical Infectious Diseases

Volumn 64, Issue 6, 2017, Pages E34-E65

  Tunkel, Allan R ^a   Hasbun, Rodrigo ^b   Bhimraj, Adarsh ^c   Byers, Karin ^d   Kaplan, Sheldon L ^e   Scheld, W Michael ^f   van de Beek, Diederik ^g   Bleck, Thomas P ^h   Garton, Hugh J L ⁱ   Zunt, Joseph R ^j  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h RUSH MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

central nervous system infections; cerebrospinal fluid drains; cerebrospinal fluid shunts; meningitis; ventriculitis

Indexed keywords

EID: 85071705288     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw861     Document Type: Article

References (211)

1. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Going from evidence to recommendations. BMJ 2008; 336:1049–51.
2. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Incorporating considerations of resources use into grading recommendations. BMJ 2008; 336:1170–3.
3. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ 2008; 336:995–8.
4. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924–6.
5. Jaeschke R, Guyatt GH, Dellinger P, et al; GRADE Working Group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337:a744.
6. Edwards RJ, Drake JM. Cerebrospinal fluid devices. In: Winn, HR, ed. Youmans & Winn Neurological Surgery. 7th ed. 2017: 1638–43.
7. Renier D, Lacombe J, Pierre-Kahn A, Sainte-Rose C, Hirsch JF. Factors causing acute shunt infection. Computer analysis of 1174 operations. J Neurosurg 1984; 61:1072–8.
8. Younger JJ, Simmons JC, Barrett FF. Operative related infection rates for ventriculoperitoneal shunt procedures in a children’s hospital. Infect Control 1987; 8:67–70.
9. Quigley MR, Reigel DH, Kortyna R. Cerebrospinal fluid shunt infections. Report of 41 cases and a critical review of the literature. Pediatr Neurosci 1989; 15:111–20.
10. Kontny U, Höfling B, Gutjahr P, Voth D, Schwarz M, Schmitt HJ. CSF shunt infections in children. Infection 1993; 21:89–92.
11. Piatt JH Jr, Carlson CV. A search for determinants of cerebrospinal fluid shunt survival: retrospective analysis of a 14-year institutional experience. Pediatr Neurosurg 1993; 19:233–41; discussion 42.
12. McGirt MJ, Leveque JC, Wellons JC 3rd, et al. Cerebrospinal fluid shunt survival and etiology of failures: a seven-year institutional experience. Pediatr Neurosurg 2002; 36:248–55.
13. Vinchon M, Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst 2006; 22:692–7.
14. Conen A, Walti LN, Merlo A, Fluckiger U, Battegay M, Trampuz A. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008; 47:73–82.
15. Choux M, Genitori L, Lang D, Lena G. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg 1992; 77:875–80.
16. Winston KR. Hair and neurosurgery. Neurosurgery 1992; 31:320–9.
17. Morissette I, Gourdeau M, Francoeur J. CSF shunt infections: a fifteen-year experience with emphasis on management and outcome. Can J Neurol Sci 1993; 20:118–22.
18. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362:146–54.
19. Simon TD, Butler J, Whitlock KB, et al. Risk factors for first cerebrospinal fluid shunt infection: findings from a multi-center prospective cohort study. J Pediatr 2014; 164:1462–8 e2.
20. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 2002; 51:170–81; discussion 81–2.
21. Ramanan M, Lipman J, Shorr A, Shankar A. A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. BMC Infect Dis 2015; 15:3.
22. Governale LS, Fein N, Logsdon J, Black PM. Techniques and complications of external lumbar drainage for normal pressure hydrocephalus. Neurosurgery 2008; 63:379–84; discussion 84.
23. Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr 2014; 13:301–6.
24. Fjelstad AB, Hommelstad J, Sorteberg A. Infections related to intrathecal baclofen therapy in children and adults: frequency and risk factors. J Neurosurg Pediatr 2009; 4:487–93.
25. Vender JR, Hester S, Waller JL, Rekito A, Lee MR. Identification and management of intrathecal baclofen pump complications: a comparison of pediatric and adult patients. J Neurosurg 2006; 104:9–15.
26. Ghosh D, Mainali G, Khera J, Luciano M. Complications of intrathecal baclofen pumps in children: experience from a tertiary care center. Pediatr Neurosurg 2013; 49:138–44.
27. Hester SM, Fisher JF, Lee MR, Macomson S, Vender JR. Evaluation of salvage techniques for infected baclofen pumps in pediatric patients with cerebral palsy. J Neurosurg Pediatr 2012; 10:548–54.
28. Wunderlich CA, Krach LE. Gram-negative meningitis and infections in individuals treated with intrathecal baclofen for spasticity: a retrospective study. Dev Med Child Neurol 2006; 48:450–5.
29. Fily F, Haegelen C, Tattevin P, et al. Deep brain stimulation hardware-related infections: a report of 12 cases and review of the literature. Clin Infect Dis 2011; 52:1020–3.
30. Stenehjem E, Armstrong WS. Central nervous system device infections. Infect Dis Clin North Am 2012; 26:89–110.
31. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology 2015; 84:810–7.
32. Kourbeti IS, Vakis AF, Ziakas P, et al. Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. J Neurosurg 2015; 122:1113–9.
33. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21–8.
34. Tsai MH, Lu CH, Huang CR, et al. Bacterial meningitis in young adults in Southern Taiwan: clinical characteristics and therapeutic outcomes. Infection 2006; 34:2–8.
35. Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 2014; 14:813–9.
36. Field MJK, Lohr, KN. Institute of Medicine Committee to advise the Public Health Service on clinical practice guidelines. Clinical practice guidelines: directions for a new program. Washington, DC: National Academies Press, 1990: 52–77.
37. George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg 1979; 51:804–11.
38. Schoenbaum SC, Gardner P, Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis 1975; 131:543–52.
39. Walters BC, Hoffman HJ, Hendrick EB, Humphreys RP. Cerebrospinal fluid shunt infection. Influences on initial management and subsequent outcome. J Neurosurg 1984; 60:1014–21.
40. Braxton EE Jr, Ehrlich GD, Hall-Stoodley L, et al. Role of biofilms in neurosurgical device-related infections. Neurosurg Rev 2005; 28:249–55.
41. Snowden JN, Beaver M, Smeltzer MS, Kielian T. Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system. Infect Immun 2012; 80:3206–14.
42. Bryant MS, Bremer AM, Tepas JJ 3rd, Mollitt DL, Nquyen TQ, Talbert JL. Abdominal complications of ventriculoperitoneal shunts. Case reports and review of the literature. Am Surg 1988; 54:50–5.
43. Piatt JH Jr, Garton HJ. Clinical diagnosis of ventriculoperitoneal shunt failure among children with hydrocephalus. Pediatr Emerg Care 2008; 24:201–10.
44. Garton HJ, Kestle JR, Drake JM. Predicting shunt failure on the basis of clinical symptoms and signs in children. J Neurosurg 2001; 94:202–10.
45. Rogers EA, Kimia A, Madsen JR, Nigrovic LE, Neuman MI. Predictors of ventricular shunt infection among children presenting to a pediatric emergency department. Pediatr Emerg Care 2012; 28:405–9.
46. Odio C, McCracken GH Jr, Nelson JD. CSF shunt infections in pediatrics. A seven-year experience. Am J Dis Child 1984; 138:1103–8.
47. Mayhall CG, Archer NH, Lamb VA, et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med 1984; 310:553–9.
48. Gerner-Smidt P, Stenager E, Kock-Jensen C. Treatment of ventriculostomy-related infections. Acta Neurochir (Wien) 1988; 91:47–9.
49. Walti LN, Conen A, Coward J, Jost GF, Trampuz A. Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. J Infect 2013; 66:424–31.
50. Chen HP, Lai CH, Chan YJ, et al. Clinical significance of Acinetobacter species isolated from cerebrospinal fluid. Scand J Infect Dis 2005; 37:669–75.
51. Hader WJ, Steinbok P. The value of routine cultures of the cerebrospinal fluid in patients with external ventricular drains. Neurosurgery 2000; 46:1149–53; discussion 53–5.
52. Wiberg K, Birnbaum A, Gradon J. Causes and presentation of meningitis in a Baltimore community hospital 1997–2006. South Med J 2008; 101:1012–6.
53. Oostenbrink R, Moons KG, Theunissen CC, Derksen-Lubsen G, Grobbee DE, Moll HA. Signs of meningeal irritation at the emergency department: how often bacterial meningitis? Pediatr Emerg Care 2001; 17:161–4.
54. Malheiro L, Gomes A, Barbosa P, Santos L, Sarmento A. Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center. Neuromodulation 2015; 18:421–7.
55. Forgacs P, Geyer CA, Freidberg SR. Characterization of chemical meningitis after neurological surgery. Clin Infect Dis 2001; 32:179–85.
56. Schade RP, Schinkel J, Roelandse FW, et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. J Neurosurg 2006; 104:101–8.
57. Tung H, Raffel C, McComb JG. Ventricular cerebrospinal fluid eosinophilia in children with ventriculoperitoneal shunts. J Neurosurg 1991; 75:541–4.
58. Fulkerson DH, Boaz JC. Cerebrospinal fluid eosinophilia in children with ventricular shunts. J Neurosurg Pediatr 2008; 1:288–95.
59. Heidemann SM, Fiore M, Sood S, Ham S. Eosinophil activation in the cerebrospinal fluid of children with shunt obstruction. Pediatr Neurosurg 2010; 46:255–8.
60. Pfisterer W, Mühlbauer M, Czech T, Reinprecht A. Early diagnosis of external ventricular drainage infection: results of a prospective study. J Neurol Neurosurg Psychiatry 2003; 74:929–32.
61. Pfausler B, Beer R, Engelhardt K, Kemmler G, Mohsenipour I, Schmutzhard E. Cell index–a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage? Acta Neurochir (Wien) 2004; 146:477–81.
62. Brouwer MC, Thwaites GE, Tunkel AR, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet 2012; 380:1684–92.
63. Kim HI, Kim SW, Park GY, et al. The causes and treatment outcomes of 91 patients with adult nosocomial meningitis. Korean J Intern Med 2012; 27:171–9.
64. Nigrovic LE, Malley R, Macias CG, et al; American Academy of Pediatrics, Pediatric Emergency Medicine Collaborative Research Committee. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics 2008; 122:726–30.
65. Banks JT, Bharara S, Tubbs RS, et al. Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. Neurosurgery 2005; 57:1237–43; discussion -43.
66. Steinbok P, Cochrane DD, Kestle JR. The significance of bacteriologically positive ventriculoperitoneal shunt components in the absence of other signs of shunt infection. J Neurosurg 1996; 84:617–23.
67. CDC/NHSN Surveillance Definitions for Specific Types of Infections. January 2015. Available at: www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current. pdf. Accessed 11 April 2016.
68. Sundbärg G, Nordström CH, Söderström S. Complications due to prolonged ventricular fluid pressure recording. Br J Neurosurg 1988; 2:485–95.
69. Palabiyikoglu I, Tekeli E, Cokca F, et al. Nosocomial meningitis in a university hospital between 1993 and 2002. J Hosp Infect 2006; 62:94–7.
70. Marinovic T, Skrlin J, Vilendecic M, Rotim K, Grahovac G. Multiple Aspergillus brain abscesses in immuno-competent patient with severe cranio-facial trauma. Acta Neurochir (Wien) 2007; 149:629–32; discussion 32.
71. Mazumder SA, Cleveland KO. Cryptococcal meningitis after neurosurgery. Am J Med Sci 2010; 339:582–3.
72. Safdieh JE, Mead PA, Sepkowitz KA, Kiehn TE, Abrey LE. Bacterial and fungal meningitis in patients with cancer. Neurology 2008; 70:943–7.
73. Kainer MA, Reagan DR, Nguyen DB, et al; Tennessee Fungal Meningitis Investigation Team. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med 2012; 367:2194–203.
74. Smith RM, Schaefer MK, Kainer MA, et al; Multistate Fungal Infection Outbreak Response Team. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013; 369:1598–609.
75. Kauffman CA, Pappas PG, Patterson TF. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013; 368:2495–500.
76. Huy NT, Thao NT, Diep DT, Kikuchi M, Zamora J, Hirayama K. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. Crit Care 2010; 14:R240.
77. Sakushima K, Hayashino Y, Kawaguchi T, Jackson JL, Fukuhara S. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. J Infect 2011; 62:255–62.
78. Leib SL, Boscacci R, Gratzl O, Zimmerli W. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Clin Infect Dis 1999; 29:69–74.
79. Wong GK, Poon WS, Ip M. Use of ventricular cerebrospinal fluid lactate measurement to diagnose cerebrospinal fluid infection in patients with intraventricular haemorrhage. J Clin Neurosci 2008; 15:654–5.
80. Maskin LP, Capparelli F, Mora A, et al. Cerebrospinal fluid lactate in post-neurosurgical bacterial meningitis diagnosis. Clin Neurol Neurosurg 2013; 115:1820–5.
81. Stein M, Schomacher J, Scharbrodt W, Preuss M, Oertel MF. Cerebrospinal fluid lactate concentration after withdrawal of metabolic suppressive therapy in subarachnoid hemorrhage. Acta Neurochir Suppl 2012; 114:333–7.
82. Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000; 28:1828–32.
83. Berger C, Schwarz S, Schaebitz WR, Aschoff A, Schwab S. Serum procalcitonin in cerebral ventriculitis. Crit Care Med 2002; 30:1778–81.
84. Omar AS, El Shawarby A, Singh R. Early monitoring of ventriculostomy-related infections with procalcitonin in patients with ventricular drains. J Clin Monit Comput 2015; 29:759–65.
85. Li Y, Zhang G, Ma R, et al. The diagnostic value of cerebrospinal fluids procalcitonin and lactate for the differential diagnosis of post-neurosurgical bacterial meningitis and aseptic meningitis. Clin Biochem 2015; 48:50–4.
86. Deutch S, Dahlberg D, Hedegaard J, Schmidt MB, Moller JK, Ostergaard L. Diagnosis of ventricular drainage-related bacterial meningitis by broad-range real-time polymerase chain reaction. Neurosurgery 2007; 61:306–11; discussion 11–2.
87. Biesbroek JM, Verduyn Lunel FM, Kragt JJ, Amelink GJ, Frijns CJ. Culture-negative Candida meningitis diagnosed by detection of Candida mannan antigen in CSF. Neurology 2013; 81:1555–6.
88. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37:1186–9.
89. Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2000; 2:140–4.
90. Malani AN, Singal B, Wheat LJ, et al. (1,3)-β-D-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections. J Clin Microbiol 2015; 53:799–803.
91. Lyons JL, Thakur KT, Lee R, et al. Utility of measuring (1,3)-β-D-glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection. J Clin Microbiol 2015; 53:319–22.
92. Ferreira NP, Otta GM, do Amaral LL, da Rocha AJ. Imaging aspects of pyogenic infections of the central nervous system. Top Magn Reson Imaging 2005; 16:145–54.
93. Kline MW, Kaplan SL. Computed tomography in bacterial meningitis of childhood. Pediatr Infect Dis J 1988; 7:855–7.
94. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267–84.
95. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82–98.
96. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285–92.
97. Gombert ME, Landesman SH, Corrado ML, Stein SC, Melvin ET, Cummings M. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg 1981; 55:633–6.
98. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719–24.
99. Dunne WM Jr, Mason EO Jr, Kaplan SL. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 1993; 37:2522–6.
100. Gill CJ, Murphy MA, Hamer DH. Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infect 2002; 45:129–32.
101. Milstone AM, Dick J, Carson B, Siberry GK. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against Enterococcus faecalis in a child with a ventriculoperitoneal shunt infection. Pediatr Neurosurg 2007; 43:406–9.
102. Yilmaz A, Dalgic N, Müslüman M, Sancar M, Colak I, Aydin Y. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. J Neurosurg Pediatr 2010; 5:443–8.
103. Maranich AM, Rajnik M. Successful treatment of vancomycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. Mil Med 2008; 173:927–9.
104. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21:798–800.
105. Antony SJ, Hoffman-Roberts HL, Foote BS. Use of daptomycin as salvage therapy in the treatment of central nervous system infections including meningitis and shunt infections. Infect Dis Clin Pract 2012; 20:161–3.
106. Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 2011; 55:3505–9.
107. Foster DR, Rhoney DH. Enterobacter meningitis: organism susceptibilities, antimicrobial therapy and related outcomes. Surg Neurol 2005; 63:533–7; discussion 7.
108. Wolff MA, Young CL, Ramphal R. Antibiotic therapy for Enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. Clin Infect Dis 1993; 16:772–7.
109. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009; 9:245–55.
110. Moon C, Kwak YG, Kim BN, Kim ES, Lee CS. Implications of postneurosurgical meningitis caused by carbapenem-resistant Acinetobacter baumannii. J Infect Chemother 2013; 19:916–9.
111. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272–82.
112. Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 2004; 24:803–7.
113. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; doi:10.1093/cid/civ933.
114. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274–82.
115. Patterson TF, Thompson GR III, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; doi:10.1093/cid/ciw326.
116. Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurologic surgery. The intraventricular use of antibiotics. Neurosurg Clin N Am 1992; 3:343–54.
117. Tamber MS, Klimo P Jr, Mazzola CA, Flannery AM; Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 8: Management of cerebrospinal fluid shunt infection. J Neurosurg Pediatr 2014; 14 Suppl 1:60–71.
118. Infection in Neurosurgery Working Party of the British Society for Antimicrobial Chemotherapy. The management of neurosurgical patients with postoperative bacterial or aseptic meningitis or external ventricular drain-associated ventriculitis. Br J Neurosurg 2000; 14:7–12.
119. Ziai WC, Lewin JJ 3rd. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol 2009; 22:277–82.
120. Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98:1040–4.
121. Pfausler B, Haring HP, Kampfl A, Wissel J, Schober M, Schmutzhard E. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis 1997; 25:733–5.
122. Wang JH, Lin PC, Chou CH, et al. Intraventricular antimicrobial therapy in postneurosurgical gram-negative bacillary meningitis or ventriculitis: a hospital-based retrospective study. J Microbiol Immunol Infect 2014; 47:204–10.
123. Wilkie MD, Hanson MF, Statham PF, Brennan PM. Infections of cerebrospinal fluid diversion devices in adults: the role of intraventricular antimicrobial therapy. J Infect 2013; 66:239–46.
124. Ng K, Mabasa VH, Chow I, Ensom MH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. Neurocrit Care 2014; 20:158–71.
125. Imberti R, Cusato M, Accetta G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother 2012; 56:4416–21.
126. Tängdén T, Enblad P, Ullberg M, Sjölin J. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. Clin Infect Dis 2011; 52:1310–6.
127. Chen K, Wu Y, Wang Q, et al. The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy. J Crit Care 2015; 30:218 e1–5.
128. Shah SS, Ohlsson A, Shah VS. Intraventricular antibiotics for bacterial meningitis in neonates. Cochrane Database Syst Rev 2012; 7:CD004496.
129. Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy 2009; 29:832–45.
130. Brown EM, Edwards RJ, Pople IK. Conservative management of patients with cerebrospinal fluid shunt infections. Neurosurgery 2006; 58:657–65; discussion 65.
131. Arnell K, Cesarini K, Lagerqvist-Widh A, Wester T, Sjölin J. Cerebrospinal fluid shunt infections in children over a 13-year period: anaerobic cultures and comparison of clinical signs of infection with Propionibacterium acnes and with other bacteria. J Neurosurg Pediatr 2008; 1:366–72.
132. Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin Neurol Neurosurg 2002; 104:54–6.
133. Cruciani M, Navarra A, Di Perri G, et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992; 15:285–9.
134. Erritouni M, Ktaich N, Rahal JJ, et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med 2012; 2012:593578.
135. Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008; 61:461–2.
136. Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010; 29:379–81.
137. Mueller SW, Kiser TH, Anderson TA, Neumann RT. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium. Ann Pharmacother 2012; 46:e35.
138. Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005; 43:4916–7.
139. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007; 29:9–25.
140. Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 2008; 61:908–13.
141. Kestle JR, Garton HJ, Whitehead WE, et al. Management of shunt infections: a multicenter pilot study. J Neurosurg 2006; 105:177–81.
142. Simon TD, Mayer-Hamblett N, Whitlock KB, et al. Few patient, treatment, and diagnostic or microbiological factors, except complications and intermittent negative cerebrospinal fluid (CSF) cultures during first CSF shunt infection, are associated with reinfection. J Pediatric Infect Dis Soc 2014; 3:15–22.
143. Nelson JD. Cerebrospinal fluid shunt infections. Pediatr Infect Dis J 1984; 3:30–2.
144. Jones RF, Stening WA, Kwok BC, Sands TM. Third ventriculostomy for shunt infections in children. Neurosurgery 1993; 32:855–9; discussion 60.
145. Shimizu T, Luciano MG, Fukuhara T. Role of endoscopic third ventriculostomy at infected cerebrospinal fluid shunt removal. J Neurosurg Pediatr 2012; 9:320–6.
146. Yogev R. Cerebrospinal fluid shunt infections: a personal view. Pediatr Infect Dis 1985; 4:113–8.
147. Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002; 21:632–6.
148. James HE, Walsh JW, Wilson HD, Connor JD. The management of cerebrospinal fluid shunt infections: a clinical experience. Acta Neurochir (Wien) 1981; 59:157–66.
149. James HE, Walsh JW, Wilson HD, Connor JD, Bean JR, Tibbs PA. Prospective randomized study of therapy in cerebrospinal fluid shunt infection. Neurosurgery 1980; 7:459–63.
150. Whitehead WE, Kestle JR. The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons. Pediatr Neurosurg 2001; 35:205–10.
151. Turgut M, Alabaz D, Erbey F, et al. Cerebrospinal fluid shunt infections in children. Pediatr Neurosurg 2005; 41:131–6.
152. Williams TA, Leslie GD, Dobb GJ, Roberts B, van Heerden PV. Decrease in proven ventriculitis by reducing the frequency of cerebrospinal fluid sampling from extraventricular drains. J Neurosurg 2011; 115:1040–6.
153. Chapman PH, Borges LF. Shunt infections: prevention and treatment. Clin Neurosurg 1985; 32:652–64.
154. Stone J, Gruber TJ, Rozzelle CJ. Healthcare savings associated with reduced infection rates using antimicrobial suture wound closure for cerebrospinal fluid shunt procedures. Pediatr Neurosurg 2010; 46:19–24.
155. Tulipan N, Cleves MA. Effect of an intraoperative double-gloving strategy on the incidence of cerebrospinal fluid shunt infection. J Neurosurg 2006; 104:5–8.
156. Pirotte BJ, Lubansu A, Bruneau M, Loqa C, Van Cutsem N, Brotchi J. Sterile surgical technique for shunt placement reduces the shunt infection rate in children: preliminary analysis of a prospective protocol in 115 consecutive procedures. Childs Nerv Syst 2007; 23:1251–61.
157. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebrospinal fluid shunts: a metaanalysis. Neurosurgery 1994; 34:87–92.
158. Langley JM, LeBlanc JC, Drake J, Milner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis 1993; 17:98–103.
159. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane Database Syst Rev 2006; CD005365.
160. Alleyne CH Jr, Hassan M, Zabramski JM. The efficacy and cost of prophylactic and perioprocedural antibiotics in patients with external ventricular drains. Neurosurgery 2000; 47:1124–7; discussion 7–9.
161. Aucoin PJ, Kotilainen HR, Gantz NM, Davidson R, Kellogg P, Stone B. Intracranial pressure monitors. Epidemiologic study of risk factors and infections. Am J Med 1986; 80:369–76.
162. Clark WC, Muhlbauer MS, Lowrey R, Hartman M, Ray MW, Watridge CB. Complications of intracranial pressure monitoring in trauma patients. Neurosurgery 1989; 25:20–4.
163. Poon WS, Ng S, Wai S. CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study. Acta Neurochir Suppl 1998; 71:146–8.
164. Schultz M, Moore K, Foote AW. Bacterial ventriculitis and duration of ventriculostomy catheter insertion. J Neurosci Nurs 1993; 25:158–64.
165. Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections–an epidemiological study. Acta Neurochir (Wien) 1986; 83:20–3.
166. Smith RW, Alksne JF. Infections complicating the use of external ventriculostomy. J Neurosurg 1976; 44:567–70.
167. Wyler AR, Kelly WA. Use of antibiotics with external ventriculostomies. J Neurosurg 1972; 37:185–7.
168. Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 2008; 62 Suppl 2:688–700.
169. Camacho EF, Boszczowski I, Basso M, et al. Infection rate and risk factors associated with infections related to external ventricular drain. Infection 2011; 39:47–51.
170. Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJ. Risk factors for infections related to external ventricular drainage. Acta Neurochir (Wien) 2008; 150:209–14; discussion 14.
171. Blomstedt GC. Results of trimethoprim-sulfamethoxazole prophylaxis in ventriculostomy and shunting procedures. A double-blind randomized trial. J Neurosurg 1985; 62:694–7.
172. Sonabend AM, Korenfeld Y, Crisman C, Badjatia N, Mayer SA, Connolly ES Jr. Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review. Neurosurgery 2011; 68:996–1005.
173. Murphy RK, Liu B, Srinath A, et al. No additional protection against ventriculitis with prolonged systemic antibiotic prophylaxis for patients treated with antibiotic-coated external ventricular drains. J Neurosurg 2015; 122:1120–6.
174. Govender ST, Nathoo N, van Dellen JR. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. J Neurosurg 2003; 99:831–9.
175. Pattavilakom A, Xenos C, Bradfield O, Danks RA. Reduction in shunt infection using antibiotic impregnated CSF shunt catheters: an Australian prospective study. J Clin Neurosci 2007; 14:526–31.
176. Sciubba DM, Stuart RM, McGirt MJ, et al. Effect of antibiotic-impregnated shunt catheters in decreasing the incidence of shunt infection in the treatment of hydrocephalus. J Neurosurg 2005; 103:131–6.
177. Kan P, Kestle J. Lack of efficacy of antibiotic-impregnated shunt systems in preventing shunt infections in children. Childs Nerv Syst 2007; 23:773–7.
178. Ritz R, Roser F, Morgalla M, Dietz K, Tatagiba M, Will BE. Do antibiotic-impregnated shunts in hydrocephalus therapy reduce the risk of infection? An observational study in 258 patients. BMC Infect Dis 2007; 7:38.
179. Thomas R, Lee S, Patole S, Rao S. Antibiotic-impregnated catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis. Br J Neurosurg 2012; 26:175–84.
180. Parker SL, Anderson WN, Lilienfeld S, Megerian JT, McGirt MJ. Cerebrospinal shunt infection in patients receiving antibiotic-impregnated versus standard shunts. J Neurosurg Pediatr 2011; 8:259–65.
181. Attenello FJ, Garces-Ambrossi GL, Zaidi HA, Sciubba DM, Jallo GI. Hospital costs associated with shunt infections in patients receiving antibiotic-impregnated shunt catheters versus standard shunt catheters. Neurosurgery 2010; 66:284–9; discussion 9.
182. Parker SL, McGirt MJ, Murphy JA, Megerian JT, Stout M, Engelhart L. Comparative effectiveness of antibiotic-impregnated shunt catheters in the treatment of adult and pediatric hydrocephalus: analysis of 12 589 consecutive cases from 287 US hospital systems. J Neurosurg 2015; 122:443–8.
183. Zabramski JM, Whiting D, Darouiche RO, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg 2003; 98:725–30.
184. Harrop JS, Sharan AD, Ratliff J, et al. Impact of a standardized protocol and antibiotic-impregnated catheters on ventriculostomy infection rates in cerebrovascular patients. Neurosurgery 2010; 67:187–91; discussion 91.
185. Gutiérrez-González R, Boto GR, González N, Viudez I, Pérez-Zamarrón A, Rivero-Garvía M. Effect of antibiotic-impregnated catheters on the incidence of infection after cerebrospinal fluid shunting. Med Clin (Barc) 2008; 131:121–4.
186. Tamburrini G, Massimi L, Caldarelli M, Di Rocco C. Antibiotic impregnated external ventricular drainage and third ventriculostomy in the management of hydrocephalus associated with posterior cranial fossa tumours. Acta Neurochir (Wien) 2008; 150:1049–55; discussion 55–6.
187. Wong GK, Poon WS, Ng SC, Ip M. The impact of ventricular catheter impregnated with antimicrobial agents on infections in patients with ventricular catheter: interim report. Acta Neurochir Suppl 2008; 102:53–5.
188. Sciubba DM, McGirt MJ, Woodworth GF, Carson B, Jallo GI. Prolonged exposure to antibiotic-impregnated shunt catheters does not increase incidence of late shunt infections. Childs Nerv Syst 2007; 23:867–71.
189. Park P, Garton HJ, Kocan MJ, Thompson BG. Risk of infection with prolonged ventricular catheterization. Neurosurgery 2004; 55:594–9; discussion 9–601.
190. Holloway KL, Barnes T, Choi S, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurosurg 1996; 85:419–24.
191. Wong GK, Poon WS, Wai S, Yu LM, Lyon D, Lam JM. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73:759–61.
192. Kestle JR, Riva-Cambrin J, Wellons JC 3rd, et al; Hydrocephalus Clinical Research Network. A standardized protocol to reduce cerebrospinal fluid shunt infection: the hydrocephalus clinical research network quality improvement initiative. J Neurosurg Pediatr 2011; 8:22–9.
193. Hill M, Baker G, Carter D, et al. A multidisciplinary approach to end external ventricular drain infections in the neurocritical care unit. J Neurosci Nurs 2012; 44:188–93.
194. Korinek AM, Baugnon T, Golmard JL, van Effenterre R, Coriat P, Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2006; 59:126–33; discussion -33.
195. Korinek AM, Golmard JL, Elcheick A, et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4578 patients. Br J Neurosurg 2005; 19:155–62.
196. Barker FG 2nd. Efficacy of prophylactic antibiotics for craniotomy: a meta-analysis. Neurosurgery 1994; 35:484–90; discussion 91–2.
197. Geraghty J, Feely M. Antibiotic prophylaxis in neurosurgery. A randomized controlled trial. J Neurosurg 1984; 60:724–6.
198. Schmidt K, Gjerris F, Osgaard O, et al. Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 152 hydrocephalic patients. Neurosurgery 1985; 17:1–5.
199. Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup; American Academy of Orthopaedic Surgeons; American Association of Critical Care Nurses; American Association of Nurse Anesthetists; American College of Surgeons; American College of Osteopathic Surgeons; American Geriatrics Society; American Society of Anesthesiologists; American Society of Colon and Rectal Surgeons; American Society of Health-System Pharmacists; American Society of PeriAnesthesia Nurses; Ascension Health; Association of periOperative Registered Nurses; Association for Professionals in Infection Control and Epidemiology; Infectious Diseases Society of America; Medical Letter; Premier; Society for Healthcare Epidemiology of America; Society of Thoracic Surgeons; Surgical Infection Society. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706–15.
200. Baltas I, Tsoulfa S, Sakellariou P, Vogas V, Fylaktakis M, Kondodimou A. Posttraumatic meningitis: bacteriology, hydrocephalus, and outcome. Neurosurgery 1994; 35:422–6; discussion 6–7.
201. Heary RF, Hunt CD, Krieger AJ, Schulder M, Vaid C. Nonsurgical treatment of compound depressed skull fractures. J Trauma 1993; 35:441–7.
202. Bullock MR, Chesnut R, Ghajar J, et al; Surgical Management of Traumatic Brain Injury Author Group. Surgical management of depressed cranial fractures. Neurosurgery 2006; 58:S56–60; discussion Si–iv.
203. Friedman JA, Ebersold MJ, Quast LM. Post-traumatic cerebrospinal fluid leakage. World J Surg 2001; 25:1062–6.
204. Eftekhar B, Ghodsi M, Nejat F, Ketabchi E, Esmaeeli B. Prophylactic administration of ceftriaxone for the prevention of meningitis after traumatic pneumocephalus: results of a clinical trial. J Neurosurg 2004; 101:757–61.
205. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2006; CD004884.
206. Choi D, Spann R. Traumatic cerebrospinal fluid leakage: risk factors and the use of prophylactic antibiotics. Br J Neurosurg 1996; 10:571–5.
207. Levin S, Nelson KE, Spies HW, Lepper MH. Pneumococcal meningitis: the problem of the unseen cerebrospinal fluid leak. Am J Med Sci 1972; 264:319–27.
208. Jones SR, Luby JP, Sanford JP. Bacterial meningitis complicating cranial-spinal trauma. J Trauma 1973; 13:895–900.
209. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816–9.
210. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). 2013; 62:521–4.
211. Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822–5.